3 assets in Bilineal Acute Myeloid Leukemia

Therapeutic assets addressing Bilineal Acute Myeloid Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Azacitidine Bilineal Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P2	B (57)
Venetoclax Bilineal Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P2	B (57)
Enasidenib Bilineal Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P2	CCC (53)